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AbstrACt
Objective To ascertain contemporary approaches to the 
collection, reporting and analysis of adverse events (AEs) 
in randomised controlled trials (RCTs) with a primary 
efficacy outcome.
Design A review of clinical trials of drug interventions 
from four high impact medical journals.
Data sources Electronic contents table of the BMJ, the 
Journal of the American Medical Association (JAMA), the 
Lancet and the New England Journal of Medicine (NEJM) 
were searched for reports of original RCTs published 
between September 2015 and September 2016.
Methods A prepiloted checklist was used and single 
data extraction was performed by three reviewers with 
independent check of a randomly sampled subset to 
verify quality. We extracted data on collection methods, 
assessment of severity and causality, reporting criteria, 
analysis methods and presentation of AE data.
results We identified 184 eligible reports (BMJ n=3; 
JAMA n=38, Lancet n=62 and NEJM n=81). Sixty-two 
per cent reported some form of spontaneous AE collection 
but only 29% included details of specific prompts used to 
ascertain AE data. Numbers that withdrew from the trial 
were well reported (80%), however only 35% of these 
reported whether withdrawals were due to AEs. Results 
presented and analysis performed was predominantly 
on ‘patients with at least one event’ with 84% of studies 
ignoring repeated events. Despite a lack of power to 
undertake formal hypothesis testing, 47% performed such 
tests for binary outcomes.
Conclusions This review highlighted that the collection, 
reporting and analysis of AE data in clinical trials is 
inconsistent and RCTs as a source of safety data are 
underused. Areas to improve include reducing information 
loss when analysing at patient level and inappropriate 
practice of underpowered multiple hypothesis testing. 
Implementation of standard reporting practices could 
enable a more accurate synthesis of safety data and 
development of guidance for statistical methodology to 
assess causality of AEs could facilitate better statistical 
practice.
IntrODuCtIOn 
The methods to analyse and report outcomes 
to measure benefit from randomised 
controlled trials (RCTs) are well developed 
but this progress has not been matched 
for adverse event (AE) outcomes. An AE is 
defined as ‘any untoward medical occurrence 
that may present during treatment with a 
pharmaceutical product but which does not 
necessarily have a causal relationship with 
this treatment’.1 An adverse drug reaction 
(ADR) is defined as ‘a response to a drug 
which is noxious and unintended …’ where 
a causal relationship is ‘at least a reasonable 
possibility’.1 2 RCTs provide an opportunity to 
compare rates of AEs between arms allowing 
causality to be evaluated. However, contem-
porary analysis and reporting practices are 
inadequate.
There are many challenges associated 
with analysing and reporting AEs in clinical 
trials. RCTs are typically designed to deter-
mine the efficacy of an intervention but are 
often underpowered to detect important 
differences in AEs between arms which may 
suggest an ADR. Often large numbers of 
AEs are reported during a study, sometimes 
exceeding the number of patients in the 
clinical trial. Performing hypothesis tests on 
these AEs would lead to issues of multiplicity; 
however, any adjustment for multiplicity 
would make a ‘finding untenable’.3 4 The 
use of hypothesis testing may result in the 
medicinal product being deemed unsafe and 
a trial being halted too early due to a chance 
imbalance, or conversely deemed safe and 
strengths and limitations of this study
 ► This is the first review to examine and quantify the 
methods used for adverse event analysis in ran-
domised controlled trials published in high impact 
general medical journals.
 ► This review identifies methodological weakness that 
need to be addressed as well as good practice that 
could be adopted.
 ► Articles included in this review were published in 
four of the top ranked general medical journals, 
therefore results are likely to be biased towards bet-
ter practice.
 ► Included articles are only for year 2015–2016 and 
as such may not reflect current practice.
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not stopped early enough resulting in more patients than 
necessary suffering an ADR.3 5 6 Unlike efficacy outcomes 
which are well defined and restricted in number at the 
planning stage of an RCT, we collect numerous, unde-
fined AEs in RCTs. Furthermore, AE collection requires 
additional information to be obtained on factors such as 
severity, timing and duration, number of occurrences and 
outcome, which for our efficacy outcomes would have all 
been predefined.
Previous studies have examined the methods for AE 
collection and presentation only, and highlighted the 
inadequacies in AE reporting in journal articles.7–16 
In 2004, the Consolidated Standards of Reporting 
Trials (CONSORT) Group produced an extension to 
their guidelines for reporting trial results to cover the 
reporting of harms, however implementation of these 
guidelines has been shown to be poor.10 14–17 Recently, 
a joint pharmaceutical/journal collaboration published 
practical guidance and examples on what should 
be reported in journal articles and how it should be 
displayed to ensure transparency and aid clinical inter-
pretation. They promote the use of clinical judgement in 
reporting rather than mandatory guidance.18 While this 
work has been undertaken there remains uncertainty 
about practice for reporting and presenting AE data, 
and in addition the analysis practice for AEs remains a 
neglected area for review.
The aim of this review was to evaluate contemporary 
practice for collection, reporting and analysis of AEs in 
RCTs where the primary outcome was efficacy. The aim 
being to identify and promote any areas of good practice, 
while highlighting any areas for improvement.
MethODs
search strategy
The top four general medical journals as ranked by 
impact factors that publish clinical trials of drug inter-
ventions were selected: the BMJ (Impact Factor 20.79), 
the Journal of the American Medical Association (JAMA, IF 
44.41), the Lancet (IF 47.83) and the New England Journal 
of Medicine (NEJM, IF 72.41). Impact factors quoted are 
from 2016 to reflect the time period from which the arti-
cles were drawn. High impact journals were chosen as 
we would expect practice in these journals to be of high 
standard as they include statistical and methodological 
review. We limited the search to four journals after an 
initial scoping review revealed around 100 studies would 
be eligible for inclusion, which was a feasible number to 
review given the time and resources available and would 
provide a sufficient number to evaluate practice. One 
reviewer manually searched the electronic contents table 
of the journals for reports of original RCTs published 
between September 2015 and September 2016, inclu-
sive. Any queries regarding eligibility were reviewed and 
discussed with a second reviewer.
selection criteria
The inclusion criteria were phase II–IV RCTs of drug 
interventions where the primary outcome was efficacy 
of the intervention. We did not restrict according to 
number of treatment arms and included both parallel 
and cluster RCTs. We excluded cross-over RCTs, RCTs 
with adaptive randomisation, observational studies, 
case reports, editorials and letters. We also excluded 
RCTs where the intervention was not a drug product 
(ie, not classified as a clinical trial of an investigational 
medicinal product). As the study aimed to assess how 
the authors report and analyse AEs in studies where the 
primary outcome was efficacy, trials that were specifically 
designed to investigate safety as a primary outcome were 
not included.
Data extraction
Potentially eligible articles were identified based on 
titles and abstracts and the full text of these studies were 
retrieved. Supplementary material was also reviewed if 
readers were referred here from the main article for 
further results. Online supplementary table A1 lists all 
data items captured with guidance given to the reviewers 
for extraction. The items to be extracted were based on 
the work by Cornelius et al and the CONSORT harm 
extension with additional items added to capture more 
specific information on analysis practices.11 17 Specifi-
cally, we focused on the following areas: how AE data 
were collected (mode of collection, timing) and defined 
(coding, attribution); how AEs were assessed in terms 
of severity of the event or relatedness to the medical 
intervention; if there was any planned AE analysis (final 
and interim monitoring plans and analysis populations); 
how events were selected for inclusion in the journal 
article; how summary event information was presented 
in the journal article and how AEs were analysed.11 A 
more detailed rationale for the choice of items extracted 
is provided in the online supplementary material table 
A2.
A data extraction sheet was piloted and then single data 
extraction was performed by three reviewers (RP, VC and 
LH) with 10% independent check of a randomly sampled 
subset to verify quality. Queries were also informally 
discussed between reviewers on an ongoing basis. Where 
specific items were flagged for poor agreement these 
were re-extracted. Any queries during data extraction 
were shared and disagreements between reviewers were 
resolved through discussion.
Data analysis
The proportion of trials reporting each item, 3–4 and 
8–34 in online supplementary table A1 were calculated 
and summary statistics (median and ranges) were calcu-
lated for items 5–7. All analyses were performed in Stata 
V.15.19 A risk of bias assessment was not undertaken as 
this study aimed to describe best practice and not eval-
uate outcomes.
 o
n
 11 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024537 on 1 March 2019. Downloaded from 
3Phillips R, et al. BMJ Open 2019;9:e024537. doi:10.1136/bmjopen-2018-024537
Open access
Patient and public involvement
This review forms part of a wider research project that was 
developed with input from a range of patient representa-
tives. There were no study participants directly involved 
in this review but the original proposal and patient and 
public involvement (PPI) strategy were reviewed by 
service user representatives (with experience as clinical 
trial participants and PPI advisors) who provided advice 
specifically with regard to communication and dissemina-
tion to patient and public groups.
results
Data extraction
A total of 585 items were extracted twice across all three 
reviewers to check the quality of the data extraction. 
A total of 95 discrepancies were identified. This gave 
agreement of 84%. During this independent check 
several items were flagged for potential poor agreement. 
These items were 100% independently extracted by one 
author and verified. The items were: study duration; the 
AE collection method; timing of collection; how binary 
harm outcomes were summarised; whether continuous 
outcomes were dichotomised; if continuous outcomes 
were left as continuous how they were analysed.
study characteristics
The search identified 184 eligible trial reports (BMJ n=3; 
JAMA n=38, Lancet n=62 and NEJM n=81) in which a total 
of 496 911 participants were randomised with a median 
of 556 participants per trial (range 30, 205513; IQR 281, 
1704). The median trial follow-up was 52 weeks (range 
48 hours to 10 years; IQR 24, 104 weeks) and 93% were 
multicentre trials. Fifty per cent of studies had an active 
comparator and over 50% of trials received some element 
of industry funding (table 1).
Collection and assessment methods
Sixty-two per cent (n=114) of reports made reference 
to some form of passive (eg, spontaneously reported by 
patients) AE monitoring or collection methods. Of these, 
only 46.5% (53/114) or 29% of total reports included 
specific details (prompts, eg, questions about specific 
events or AEs in general, questionnaires or diaries) 
regarding these collection methods (online supplemen-
tary table A3, examples 1–2).20 21 The timing of collection 
was well documented (91%, 48 out of 53 reports) in the 
reports that included specific details about the prompts 
used to collect AEs. Although specific details on clinical 
examinations (eg, vital signs and blood pressure) and 
laboratory tests were not widely reported (only 57% of 
reports (95 out of 166 reports with clinical examinations 
and/or laboratory results presented) included details on 
the timing of such assessments), it was often clear from 
the results presented that participants had undergone 
these assessments (83% and 79% of studies reported clin-
ical and laboratory results, respectively) (table 2).
Prespecified analysis
Thirty-one per cent of reports provided information on 
the planned analysis for AEs in the statistical analysis 
section of the paper and 45% prespecified a safety popu-
lation (online supplementary table A3, examples 3–4 and 
table 2).22 23 A quarter of trials reported planned interim 
analysis with stopping criteria (table 2), five (2.7%) of 
which included specific criteria on stopping for a harmful 
event (online supplementary table A4).24–28
selection of Aes and reporting practices
Two reports only made generic statements regarding 
AE data: ‘there were no significant adverse events related to the 
procedure’ and ‘no excess in mortality or major adverse events 
were found…’. Three reports made no mention of AEs 
throughout the manuscript.29–33
Twenty-four (13%) trials only provided a summary of 
the number of AEs or serious AEs rather than listing the 
actual AEs that occurred. For example, ‘Six serious adverse 
events occurred in the acetaminophen group and 12 in the 
Table 1 Characteristics of included studies
Characteristic
n=184
Min, maxMedian (IQR)
Sample size 556 (281, 1704) 30, 205 513
Centres* 35 (12, 100) 1, 1368
Trial duration 
(weeks)†
52 (24, 104) 0.3, 521
n %
Journal
  BMJ 3 1.6
  JAMA 81 44.0
  Lancet 38 20.7
  NEJM 62 33.7
Funded by
  Public 70 38.3
  Industry 80 43.7
  Both 33 18.0
Centre 
  Single centre 12 7.0
  Multicentre 161 93.0
Control
  Placebo 95 51.6
  Active 80 43.5
  Both 8 4.4
  Neither‡ 1 0.5
*Eleven reports did not specify the number of centres. 
†Two reports did not specify trial duration.
‡One trial compared interventional drug to behavioural change 
intervention.
JAMA, Journal of the American Medical Association; max, 
maximum; min, minimum; NEJM, New England Journal of 
Medicine. 
 o
n
 11 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024537 on 1 March 2019. Downloaded from 
4 Phillips R, et al. BMJ Open 2019;9:e024537. doi:10.1136/bmjopen-2018-024537
Open access 
ibuprofen group’.34 Of these 24 trials, 10 did provide specific 
details of the types of events in an appendix. This means 
8% of trials either did not report AEs or only included a 
summary (table 3).
Eighty-nine per cent of trials reported a subset of all the 
AEs they collected. How AEs are ‘selected’ for inclusion 
in the article was not consistent or clear, and in 3% of 
studies it was impossible to discern how the authors had 
selected the AEs they presented for inclusion. Twenty-six 
per cent of reports selected events based on a frequency 
threshold, for example, events experienced by >x% in 
any group; 9% of reports used a measure of severity to 
Table 2 Collection, assessment and analysis methods reported by studies
Section Component Data item
n=184
n %
Collection
How was AE/harm information collected?
Passive collection 114 62.0
Prompted collection (n=114) 53 46.5
No method of collection reported 70 38.0
Did they undertake proactive screening?
Clinical examinations 153 83.2
Laboratory tests 146 79.4
  Timing of prompted collection specified (n=53) 48 90.6
  Timing of active collection specified (n=166) 95 57.2
Which, if any, dictionary was used to code AE data?
CTCAE 18 9.8
MedDRA 43 23.4
CTCAE and MedDRA 1 0.5
DAIDS 2 1.1
ICD-10 1 0.5
Researcher defined 2 1.1
Other 3 1.6
No dictionary reported 114 62.0
Assessment
Who assigned attribution to study drug?
Blinded assessor 9 4.9
Unblinded assessor 7 3.8
Both 1 0.5
Not specified 164 89.1
Not applicable* 3 1.6
Analysis
Was any analysis for AEs specified in the methods section?
Yes 57 31.0
Was a population for AE analysis specified?
Yes 82 44.6
Was there a planned interim analysis with stopping criteria?
No 138 75.0
Yes for efficacy 24 13.0
Yes for efficacy and futility 11 6.0
Yes for efficacy and safety 3 1.6
Yes for efficacy, futility and safety 2 1.1
Yes but no other details given 6 3.3
Denominator specified in item column if it differs from total sample. 
*Three reports made no reference to AE data throughout the article. 
AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; DAIDS, The Division of AIDS; ICD-10, International Classification 
of Diseases 10th revision; MedDRA, Medical Dictionary for Regulatory Activities. 
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Table 3 Summaries of results presented by studies
Component Data item
n=184
n %
What was reported in the manuscript?
Actual AE terms 73 39.7
Summaries of AE type (eg, AE, SAE) 24 13.0
Both 80 43.5
Neither 7 3.8
What was reported in the appendix?
Actual AE terms 76 41.3
Summaries of AE type (eg, AE, SAE) 7 3.8
Both 22 12.0
Neither 3 1.6
Not applicable* 76 41.3
Which population was the AE analysis performed on?
All randomised 54 29.4
Those that took at least a single dose 75 40.8
Other 35 19.0
Not specified 17 9.2
Not applicable† 3 1.6
Were drop-outs/withdrawals reported?
No 33 17.9
Yes by treatment arm 144 78.3
Yes overall 2 1.1
Not applicable‡ 5 2.7
  Were withdrawals due to AEs reported? (n=146)
No 89 61.0
Yes 51 34.9
Not applicable§ 6 4.1
  Were specific AEs causing withdrawals reported? (n=51)
No 39 76.5
Yes 12 23.5
How were binary AE outcomes summarised by arm?
Not summarised¶ 6 3.3
Number of people with an event 154 83.7
Number of events 11 6.0
Both 12 6.5
Unclear 1 0.5
Were frequencies of AEs reported by arm?
No 5 2.7
Yes for some 13 7.1
Yes for all 160 87.0
Not applicable¶ 6 3.3
Were percentages of AEs reported by arm?
No 18 9.8
Yes for some 25 13.6
Yes for all 135 73.4
Continued
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Component Data item
n=184
n %
Not applicable¶ 6 3.3
Were between arm differences and 95% CI of AEs reported?
No 141 76.6
Yes for some 18 9.8
Yes for all 19 10.3
Not applicable¶ 6 3.3
Were statistical significance tests between arms on AEs reported?
No 92 50.0
Yes for some 31 16.9
Yes for all 55 29.9
Not applicable¶ 6 3.3
Were continuous AEs outcomes dichotomised for summaries?
No 10 5.4
Yes for some 28 15.2
Yes for all 108 58.7
Not applicable 38 20.7
If continuous outcomes were left as continuous what between arm analyses was performed? (n=38)
  Differences in measures of central tendency estimated with 95% CI
No 23 60.5
Yes for some 1 2.6
Yes for all 14 36.8
  Between arm hypothesis tests performed
No 12 31.6
Yes for some 2 5.3
Yes for all 24 63.2
Were any ‘signal detection’ approaches used?
No 184 100.0
Yes 0 0.0
Were there any graphical presentations of AE outcomes?
No 162 88.0
Yes 22 12.0
Were summaries of severity rating of AEs reported?
No 103 56.0
Yes for some 41 22.3
Yes for all 35 19.0
Not applicable** 5 2.7
Were number of SAEs reported?
No 44 23.9
Yes overall 2 1.1
Yes by treatment arm 132 71.7
Not applicable†† 6 3.3
  For SAEs was relatedness given? (n=134)
No 77 57.5
Yes for some 18 13.4
Table 3 Continued 
Continued
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select events, for example, AEs of grade 3 or higher; 23% 
of reports included events based on seriousness and 8% 
included AEs based on relatedness to treatment (percent-
ages are not independent as the majority of reports used 
several different criteria for selection). Online supple-
mentary tables A5 and A6 provide full details of selection 
criteria used.
We found that 41% of trials analysed AEs in partici-
pants that received at least one dose, 29% of trials used 
all randomised participants and 9% did not specify the 
analysis population (table 3). Further details on analysis 
populations used are given in online supplementary table 
A7.
Nearly 80% of trials reported the number of partici-
pants who withdrew from the trial; of these 35% (51 of 
146 reports) reported whether the withdrawals were due 
to AEs and of these 24% (12 of 51 reports) reported the 
actual events that caused withdrawals. Results presented 
and analysis performed was predominantly on ‘patients 
with at least one event’ with 84% of reports providing 
no information on the number of events occurring. An 
example of how to incorporate information on number of 
events is presented in the study by Lind et al.35 Forty-one 
per cent of trials reported information on the severity of 
AEs. Five per cent of trials included a report of at least one 
event with duration, but presenting such data is limited in 
the main report. The trials that did present this informa-
tion did so in a variety of ways. For example, incorporating 
the information into the AE table with summary statistics 
such as the mean duration of certain events or presenting 
it for a subgroup of events in the footnotes of AE tables, 
for example, ‘One event of non-serious squamous cell carci-
noma (day 210, resolved on day 215; adalimumab treatment 
was not interrupted)’.36–38 Twenty-eight per cent of reports 
included information on the timing of AEs (table 3).
Serious AEs were typically well documented (73%) and 
six reports (3%) explicitly stated that no serious events 
had occurred. However, for 44 reports (24%) it was not 
possible to discern if no serious events had occurred 
or whether they were simply omitted from the report. 
Forty-two per cent (57 of 134 reports) of reports included 
details on whether the events had been classified as 
related to the intervention (table 3).
Analysis of Ae outcomes
The majority of trials summarised binary outcomes using 
frequencies (94%) and percentages (87%). Despite a 
lack of power to undertake formal hypothesis testing, 
47% reported p values for binary outcomes. For example, 
‘There were no between-group differences in the rate of patients 
with at least one adverse event (16.7% (14 patients) in the 
clopidogrel group vs 21.8% (19 patients) in the placebo group; 
Component Data item
n=184
n %
Yes for all 38 28.4
Yes overall 1 0.8
Were there any AEs where information on duration of events was reported?
No 175 95.1
Yes 9 4.9
Were there any AEs where information on the time of occurrence of events was reported?
No 132 71.7
Yes 52 28.3
If any significance tests were performed on AEs was multiplicity of events accounted for?
No 81 44.0
Yes 3 1.6
Not applicable 100 54.4
Did the report reference the CONSORT extension to harms?
No 184 100.0
Yes 0 0.0
*Make no reference to the appendix.
†Three reports made no reference to AE data throughout the article. 
‡Five reports indicate no withdrawals. 
§Six reports specify the number of withdrawals and reasons but none of the reasons are related to AEs. 
¶This includes three reports with no AE data (as per footnote †), two reports that provide generic statements regarding AE data and one 
report that only reported continuous outcomes.
**This includes three reports with no AE data and two reports that provide generic statements regarding AE data (as per footnote ¶).
††Six papers specifically state that no SAEs occurred.
AE, adverse event; CONSORT, Consolidated Standards for Reporting Trials; SAE, serious adverse event. 
Table 3 Continued 
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difference, −5.2% (95% CI −17% to 6.6%); p=0.44)’. 
However, with a total safety population of 171 such a test 
would have only had 13% power to detect such a differ-
ence and was therefore substantially underpowered. The 
conclusion that ‘No significant increase in adverse events was 
observed’ makes no reference to the 95% CI presented 
which indicates that the findings were in fact compatible 
with a 17% decrease in experiencing at least on AE as well 
as a near 7% increase.39
There was a pervasive practice (59%) of categorising 
continuous clinical and laboratory outcomes. Of the trials 
that did not dichotomise continuous AE data, nearly 70% 
performed some form of statistical significance testing 
(table 3). While continuous outcomes do not suffer to 
the same degree regarding lack of power, multiple testing 
is still a problem; however, no multiplicity corrections for 
continuous outcomes were performed.
Of the trials that performed statistical significance 
testing on AE data, only three made an adjustment 
for multiplicity of tests (all three on dichotomised 
outcomes).36 40 41 Two of which used a Bonferroni correc-
tion and adjusted for the number of pairwise comparisons 
between each of the treatment groups for each individual 
event rather than the total number of significance tests 
performed. As such, both analyses would have still been 
affected by issues of multiple testing.
Twelve per cent of reports used graphs to illustrate AE 
data (table 3). The CONSORT extension highlighted the 
value of graphs for summarising such data, especially for 
conveying information on time-to-event outcomes.42 An 
example of such a plot is included in the study by Lingvay 
et al43 (see supplementary eFigure2 of reference 43). 
We assessed any reference to the CONSORT harm 
extension and found that none of the included studies 
mentioned it. Of the four journals included in the 
review, the Lancet was the only journal that made specific 
reference to the harm extension in their guidelines to 
the authors.
DIsCussIOn
The safety profile of a medicinal product is estab-
lished through evidence collected from several sources 
including clinical trials, observational studies and spon-
taneous reports.44 The advantage of clinical trial data is 
that these provide a controlled comparison of the rate of 
AEs allowing causality to be evaluated but have the disad-
vantage that the sample size is often not large enough to 
detect rare ADRs.
To ensure that a useful and comprehensive picture of 
the safety profile is provided to all relevant parties clear 
reporting of AEs from clinical trials is required. Recent 
research has shown the quality of reporting is substan-
dard.7–16 The aim of this study was to review contempo-
rary practice across four leading medical journals for AE 
collection, reporting and analysis practices, highlighting 
any areas for improvement and examples of good prac-
tice. We found that the collection, reporting and analysis 
of AE data in clinical trials is inconsistent and RCTs as a 
source of safety data are underused. Analysis of AE was 
often inappropriate with suboptimal practice including 
ignoring valuable information on repeated events and 
inappropriate practice of underpowered multiple hypoth-
esis testing.
Collection and assessment methods
The CONSORT extension to harm was developed with the 
aim to improve reporting of safety data in RCTs.42 None 
of the included studies referenced the CONSTORT harm 
extension and of the items in our review that are covered 
in CONSORT many were not well reported.17 This suggests 
that the CONSORT extension is not being routinely 
adopted by the authors to aid their reporting. Most jour-
nals now request that the authors include a completed 
CONSORT checklist when they submit their article but we 
are not aware of any journal that request the CONSORT 
harm extension to also be submitted. Of the four journals 
in this review, the Lancet is the only journal that makes 
specific reference to the harm extension in their guide-
lines to the authors. The CONSORT statement contains 
a single item related to safety, item 19: ‘all important 
harms or unintended effects in each group’ should be 
reported.42 This may explain why some items listed on the 
CONSORT extension for harm were reported by so few 
trials. The mandatory submission of CONSORT harms by 
journals may support better reporting.
We found that the method of AE collection was poorly 
reported. This has important implications for the type 
and frequency of AEs reported with ‘passive collec-
tion resulting in fewer recorded AEs’.45 46 Where the 
method was given the timing of collection was typically 
also reported and we would recommend continuation of 
this practice. The frequency of AE collection has further 
important implications on the number of events reported. 
More frequent assessment and longer follow-up will result 
in more AEs reported.17 It is important to consider these 
factors when making conclusions about the safety profile.
The method of attribution between drug and AE was 
another area where reporting practice was inadequate. 
However, the joint pharmaceutical/journal collaboration 
indicate that such attribution has ‘limited value’ given the 
‘inherent subjectivity in such attribution’.18
Prespecified analysis
We found that formal assessments of AEs regarding stop-
ping for emerging ADRs using statistical rules was rare. 
Subjective assessments of overwhelming amounts of data 
could easily lead to potential signals of harm being missed. 
There could be benefits to incorporating more objective 
statistical methods alongside clinical review to assist the 
evaluation of AE information to help better identify drug 
harm relationships. Graphical displays have gone some 
way towards aiding interpretation.47–51
selection of Aes and reporting practices
Due to space constraints in journal reports AE information is 
often included in the appendix. While we encourage use of 
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appendices and supplementary material for including addi-
tional detail on AEs, we caution the authors against depos-
iting all AE data into such documents without attempting to 
present a summary of the AE profile in the main article. It 
is important that the main report strikes a balance between 
efficacy and harm therefore allowing a risk-benefit assess-
ment to be made solely from the article.
The failure to report any information on AEs restricts 
interpretation and prevents a risk-benefit assessment. We 
identified two reports that made generic summaries of the 
overall safety profile and it was clear in both that there had 
been harmful effects. However, the authors did not include 
any further information. Three reports contained no infor-
mation leaving readers uninformed as to any additional 
information these studies may provide on the safety profile. 
Ambiguous reporting prevents building an accurate picture 
of the safety profile. As such profiles are developed on accu-
mulating evidence, it is important that each study report to 
the same standard and information is not wasted.
We found that the selection criteria used by the authors 
to decide what AEs to include in the report were arbitrary 
and inconsistent. This will have important implications 
when synthesising data across studies to construct safety 
profiles. Authors would benefit from guidance to facilitate 
consistency but research in this area is lacking. Lineberry 
et al recommended clinically relevant events that should 
always be reported (deaths, serious AEs and events leading 
to discontinuation of intervention) and criteria that should 
be considered when deciding what other AEs to report, for 
example, interest based on the disease(s) under investiga-
tion, comorbidities of the study population, intervention 
mechanism, trial duration.18 Standard outcomes for a drug 
class would be one potential solution to avoid issues of incon-
sistency suggested by Cornelius et al.11
CONSORT recommend that AE analyses should be 
performed on the intention-to-treat (ITT) population 
to maintain the random assignment.17 However, it is 
clear from our review that this population label is not 
always appropriately and consistently applied. There is 
a tendency for studies to make modifications to the ITT 
population. Using the ITT or modified ITT population is 
likely to underestimate the risk by inflating the denomi-
nator with participants who may have never received the 
study drug.52 Such estimates are appropriate for health 
economic evaluations where estimates of the cost-effec-
tiveness will inform policy level decisions regarding how 
to treat the population. However, a more appropriate 
population for AE analysis to inform prescriber and 
patient decisions may be those that receive at least one 
dose. It is important that the authors clearly define and 
specify a suitable safety analysis population and consider 
how this affects their conclusions.
Proxy outcomes can be used as a measure of the impact of 
AEs on patients. Examples include the number of withdrawals 
due to any reason, withdrawals due to AEs, the number 
of events an individual experiences, the severity of the AE 
and the duration. A high proportion of trials reported with-
drawal for any reason and this is likely to be as a result of the 
CONSORT recommendations.42 The other outcomes were 
not frequently reported and increasing this could facilitate 
interpretation.17 This information would permit better evalu-
ation of the impact of AEs and the tolerability of the interven-
tion to inform patients’ and clinicians’ treatment decisions. 
Reporting numbers that experience at least one event only 
and not providing information on repeated events masks 
valuable information that may be important to the patient 
and the cost-effectiveness evaluation. For example, chronic, 
repeated headaches over an extended duration will have an 
important impact for patients compared with a single head-
ache or headaches over a short duration but it is not possible 
to distinguish between these two scenarios when reported as 
‘at least one event’.18 Severity of events was also an important 
aspect that was often not differentiated. For example, there 
would be a different impact on patients’ quality-of-life with 
mild compared with severe nausea, which could lead to 
changes in dosing regimens. Displaying such information 
for all AEs in tables would soon become overwhelming and 
make interpretation difficult. Graphical approaches have 
been suggested as a solution to aid review. Examples of such 
a plot can be found in UW–Madison SDAC.53 Online appen-
dices and supplementary material provide more opportunity 
to include this important information.
Table 4 Recommendations to improve adverse event analysis and reporting in clinical trial report publications
Recommendation
Analysis Incorporate objective statistical methods to assist the evaluation of adverse event information.
Consider avoiding dichotomising continuous data.
When count outcomes are available (such as repeated events within participants) use appropriate statistical 
methods.
Clearly define exposure and specify a suitable safety analysis population.
Use graphical approaches to help summarise large amounts of data.
Reporting Report adverse event data according to the CONSORT harm checklist.
Increase the uptake of mandatory submission of CONSORT harm by journals.
Include a relevant summary of the adverse event profile in the main article. Resist depositing all adverse event 
data into appendices without summarising. 
CONSORT, Consolidated Standards for Reporting Trials. 
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For serious AEs information on the time of likely onset 
can be useful information to inform patient monitoring 
plans. For example, the documented risk of suicide and 
suicidal ideation within the first few weeks of starting an 
antidepressant allows patients and prescribers to remain 
alert and monitor closely for this period. Nearly a third 
of reports included such information and we would 
encourage the authors to adopt this practice.
Analysis of Ae outcomes
The majority of trials in this review included a balanced 
report of AEs alongside benefit. However, many included 
generic statements regarding the safety profile such as 
‘the intervention was well tolerated’ or ‘the intervention 
exhibited a good safety profile’ and these were frequently 
based on post hoc statistical tests. Guidelines caution 
against such tests.18 The results of which are difficult to 
interpret as a lack of significance does not indicate that 
the intervention is safe and conversely multiple testing 
without adjustment will increase the number of signifi-
cant differences due to chance.54 55
Graphs are an efficient method to convey and inter-
pret large amounts of data and can make it easier to flag 
potential safety signals.50 51 53 Twelve per cent of studies 
included in the review used graphs to present AE data 
and an example of one such report is given in the study by 
Coovadia et al56 (see online supplementary eTable of refer-
ence 56).
Recommendations for consideration for immediate 
adoption by the clinical trial community are summarised in 
table 4.
limitations of trials
Trials are a valuable source for high-quality AE data but 
compared with observational studies have smaller sample 
size, follow-up periods and generalisability, which restrict 
the ability to detect rare ADRs, ADRs with long latency 
and drug interactions in complex populations. The 
typical duration of a trial means there is often insuffi-
cient follow-up to fully characterise the safety profile as 
it provides limited information on long-term exposure. 
Stringent inclusion criteria restrict the population the 
intervention is assessed in and so limited information on 
drug interactions is obtained.5
limitations of this study
Articles included in this review were published in four 
of the top ranked medical journals, therefore results are 
likely to be biased towards better findings than we would 
expect if we included all RCTs. Articles are only for year 
2015–2016 and as such may not reflect current practice. 
We also acknowledge that only completing 10% indepen-
dent check of extracted data would not have removed 
subjectivity from the data extraction but are happy that 
ongoing discussion between the authors to clarify any 
queries would have kept this to a minimum. Despite these 
limitations, this review characterises what those leading 
the field are doing and provides some examples of good 
practice that could be adopted.
Conclusions and recommendations for future work
RCTs are a valuable source of information when estab-
lishing the safety profile of medicinal products. Our 
review has demonstrated that data are not being fully 
used. Analysis of AE data is frequently inappropriate 
and RCT reports published over a recent period in high 
impact general medical journals often provide insuffi-
cient and inconsistent information to allow a comprehen-
sive summary of the safety profile to be established.
This research has identified two areas that would 
benefit from future research: (i) improving the consis-
tency of reporting important AE outcomes across trials 
to facilitate comparison and synthesis. This is in line with 
work from the COMET Initiative group (http://www. 
comet- initiative. org/) and the development of CORE 
safety outcomes by drug class could be considered.7 (ii) 
Evaluation of methods to analyse AEs in RCTs.
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